Cargando…
Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India
The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlat...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323084/ https://www.ncbi.nlm.nih.gov/pubmed/35891212 http://dx.doi.org/10.3390/vaccines10071048 |
_version_ | 1784756463349006336 |
---|---|
author | Achrekar, Geetanjali C. Batra, Kavita Urankar, Yashashri Batra, Ravi Iqbal, Naved Choudhury, Sabiha A. Hooda, Deepti Khan, Roohi Arora, Suraj Singh, Aditi Chirico, Francesco Sharma, Manoj |
author_facet | Achrekar, Geetanjali C. Batra, Kavita Urankar, Yashashri Batra, Ravi Iqbal, Naved Choudhury, Sabiha A. Hooda, Deepti Khan, Roohi Arora, Suraj Singh, Aditi Chirico, Francesco Sharma, Manoj |
author_sort | Achrekar, Geetanjali C. |
collection | PubMed |
description | The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlates. Therefore, the current cross-sectional study aimed to investigate booster dose acceptability and associated predictors among the Indian population. A convenience sampling technique was utilized to recruit a sample of 687 Indian residents. A 55-item psychometric validated survey tool was used to assess booster dose acceptability, vaccine literacy and vaccine confidence. Univariate, bivariate, and multivariate statistical methods were used to analyze the data. Over 50% of participants reported their willingness to take the booster dose. Among the group not willing to take the booster dose (n = 303, 44.1%), a significantly larger proportion of respondents were unvaccinated with the primary series (12.2% vs. 5.2%, p < 0.001), had an annual income below 2.96 lacs/annum (52.8% vs. 33.1, p < 0.001), were residents of rural areas (38.0% vs. 23.2%, p < 0.001), were not living with vulnerable individuals (78.5% vs. 65.2%, p < 0.001) and did not have family/friends who had tested positive for COVID-19 (54.6% vs. 35.1%, p = 0.001). Demographic, vaccine variables and multi-theory model subscales to predict the initiation of booster dose among hesitant participants were statistically significant, R(2) = 0.561, F (26, 244) = 11.978, p < 0.001; adjusted R(2) = 0.514. Findings of this study highlight the need to develop evidence-based interventions to promote vaccine uptake, particularly among hard-to-reach communities living in developing countries. |
format | Online Article Text |
id | pubmed-9323084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93230842022-07-27 Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India Achrekar, Geetanjali C. Batra, Kavita Urankar, Yashashri Batra, Ravi Iqbal, Naved Choudhury, Sabiha A. Hooda, Deepti Khan, Roohi Arora, Suraj Singh, Aditi Chirico, Francesco Sharma, Manoj Vaccines (Basel) Article The emergence of SARS-CoV-2 mutants, waning immunity, and breakthrough infections prompted the use of booster doses of the COVID-19 vaccine to fight against the pandemic. India started booster doses in January 2022 and it is critical to determine the intention of booster dose uptake and its correlates. Therefore, the current cross-sectional study aimed to investigate booster dose acceptability and associated predictors among the Indian population. A convenience sampling technique was utilized to recruit a sample of 687 Indian residents. A 55-item psychometric validated survey tool was used to assess booster dose acceptability, vaccine literacy and vaccine confidence. Univariate, bivariate, and multivariate statistical methods were used to analyze the data. Over 50% of participants reported their willingness to take the booster dose. Among the group not willing to take the booster dose (n = 303, 44.1%), a significantly larger proportion of respondents were unvaccinated with the primary series (12.2% vs. 5.2%, p < 0.001), had an annual income below 2.96 lacs/annum (52.8% vs. 33.1, p < 0.001), were residents of rural areas (38.0% vs. 23.2%, p < 0.001), were not living with vulnerable individuals (78.5% vs. 65.2%, p < 0.001) and did not have family/friends who had tested positive for COVID-19 (54.6% vs. 35.1%, p = 0.001). Demographic, vaccine variables and multi-theory model subscales to predict the initiation of booster dose among hesitant participants were statistically significant, R(2) = 0.561, F (26, 244) = 11.978, p < 0.001; adjusted R(2) = 0.514. Findings of this study highlight the need to develop evidence-based interventions to promote vaccine uptake, particularly among hard-to-reach communities living in developing countries. MDPI 2022-06-30 /pmc/articles/PMC9323084/ /pubmed/35891212 http://dx.doi.org/10.3390/vaccines10071048 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Achrekar, Geetanjali C. Batra, Kavita Urankar, Yashashri Batra, Ravi Iqbal, Naved Choudhury, Sabiha A. Hooda, Deepti Khan, Roohi Arora, Suraj Singh, Aditi Chirico, Francesco Sharma, Manoj Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title | Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title_full | Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title_fullStr | Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title_full_unstemmed | Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title_short | Assessing COVID-19 Booster Hesitancy and Its Correlates: An Early Evidence from India |
title_sort | assessing covid-19 booster hesitancy and its correlates: an early evidence from india |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323084/ https://www.ncbi.nlm.nih.gov/pubmed/35891212 http://dx.doi.org/10.3390/vaccines10071048 |
work_keys_str_mv | AT achrekargeetanjalic assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT batrakavita assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT urankaryashashri assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT batraravi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT iqbalnaved assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT choudhurysabihaa assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT hoodadeepti assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT khanroohi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT arorasuraj assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT singhaditi assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT chiricofrancesco assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia AT sharmamanoj assessingcovid19boosterhesitancyanditscorrelatesanearlyevidencefromindia |